These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 37586826)

  • 1. Impact of Coronavirus Disease 2019 on Intravitreal Antivascular Endothelial Growth Factor Injection Rates in Nigerians.
    Okonkwo ON; Hassan AO; Bogunjoko T; Akinye A; Akanbi T; Agweye C
    J West Afr Coll Surg; 2024; 14(1):48-53. PubMed ID: 38486642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study.
    Leroux P; Agard E; Billant J; Levron A; Bouvarel H; Badri Y; Douma I; Pradat P; Dot C
    Ophthalmologica; 2024; 247(1):44-57. PubMed ID: 38104545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
    Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
    Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen.
    Hujanen P; Ruha H; Lehtonen E; Pirinen I; Huhtala H; Vaajanen A; Syvänen U; Tuulonen A; Uusitalo-Järvinen H
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37586826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration.
    Stattin M; Forster J; Ahmed D; Haas AM; Graf A; Krepler K; Ansari-Shahrezaei S
    J Ophthalmol; 2020; 2020():8345850. PubMed ID: 32211201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study.
    Faudi E; Gauthier AS; Delbosc B; Saleh M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2149-2156. PubMed ID: 35020019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions.
    Gillies M; Arnold J; Bhandari S; Essex RW; Young S; Squirrell D; Nguyen V; Barthelmes D
    Am J Ophthalmol; 2020 Feb; 210():116-124. PubMed ID: 31606444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.
    Kotecha D; Asselbergs FW; Achenbach S; Anker SD; Atar D; Baigent C; Banerjee A; Beger B; Brobert G; Casadei B; Ceccarelli C; Cowie MR; Crea F; Cronin M; Denaxas S; Derix A; Fitzsimons D; Fredriksson M; Gale CP; Gkoutos GV; Goettsch W; Hemingway H; Ingvar M; Jonas A; Kazmierski R; Løgstrup S; Lumbers RT; Lüscher TF; McGreavy P; Piña IL; Roessig L; Steinbeisser C; Sundgren M; Tyl B; Thiel GV; Bochove KV; Vardas PE; Villanueva T; Vrana M; Weber W; Weidinger F; Windecker S; Wood A; Grobbee DE;
    Lancet Digit Health; 2022 Oct; 4(10):e757-e764. PubMed ID: 36050271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive model for measuring real-life cost-effectiveness in eyecare: automation in care and evaluation of system (aces-rwm™).
    Tuulonen A; Kataja M; Aaltonen V; Kinnunen K; Moilanen J; Saarela V; Linna M; Malmivaara A; Uusitalo-Jarvinen H
    Acta Ophthalmol; 2022 May; 100(3):e833-e840. PubMed ID: 34263537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
    Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
    Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.